• Wondering whether EyePoint at US$13.66 still offers value after a big run, or whether most of the opportunity is already priced in.
• The stock is up 133.5% over the past year and 127.7% over three years, even though it has fallen 1.4% over the last week, 3.7% over the past month and 21.9% year to date.
• Recent market attention on EyePoint has focused on its position within the US pharmaceuticals and biotech space and how investors are reassessing risk across smaller healthcare stocks. Headlines around capital raising conditions, regulatory updates for sector peers and shifting sentiment toward higher risk growth companies have all contributed to trading activity in EyePoint.
• EyePoint currently scores 2 out of 6 on Simply Wall St's valuation checks. You can see the details in its valuation score. The rest of this article will unpack those methods and also outline a broader way to think about what the stock could be worth.

EyePoint scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: EyePoint Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s dollars. It focuses on cash that could theoretically be returned to shareholders over time.

For EyePoint, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model. The latest twelve month free cash flow is a loss of $268.3 million, and analyst-based projections show further losses through 2029, then a move to positive free cash flow of $113.95 million in 2030. Beyond the analyst horizon, Simply Wall St extrapolates additional cash flows out to 2035 using its own growth assumptions.

Bringing all those projected cash flows back to today, the model arrives at an estimated intrinsic value of $86.91 per share. Compared with the current share price of $13.66, that estimate suggests EyePoint trades at an 84.3% discount to this DCF value, so on this measure the stock screens as significantly undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests EyePoint is undervalued by 84.3%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Approach 2: EyePoint Price vs Book

For companies that are not yet producing consistent profits, price to book, or P/B, is often a useful cross check because it compares the share price with the accounting value of net assets on the balance sheet. It is less sensitive to short term swings in earnings and can still be applied when P/E is not very meaningful.

In general, higher growth expectations and lower perceived risk can justify a higher P/B ratio, while slower growth and higher risk usually point to a lower, more conservative multiple. EyePoint currently trades on a P/B of 4.97x. That is above both the Pharmaceuticals industry average of 2.70x and the peer average of 3.70x.

Simply Wall St also uses a proprietary “Fair Ratio” for P/B, which estimates what a reasonable multiple could be after factoring in elements such as earnings growth, profit margins, industry, market cap and company specific risks. This tends to be more tailored than a simple comparison with peers or the broad industry, because it adjusts for the company’s own profile rather than assuming it should trade in line with averages. In EyePoint’s case, the Fair Ratio figure is not available, so this cross check cannot indicate whether the current P/B is high or low relative to those fundamentals.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your EyePoint Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to attach a clear story about EyePoint to your own numbers for future revenue, earnings and margins. You can then link that story to a Fair Value and compare it with the current price on Simply Wall St's Community page, where Narratives are updated as news or earnings arrive and can differ widely. For example, they can range from a more cautious view that aligns with a US$20.00 Fair Value to a more optimistic view closer to US$59.30. This can help you decide whether EyePoint looks closer to a buy, sell or hold in your personal framework.

Do you think there's more to the story for EyePoint? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.